HELLO MENTERI KESIHATAN: Chinese cancer drug sudah on sale. Murah saja.

‘Saved my mum’s life’: Chinese cancer drug on sale in US after Americans travel to buy it.  Saturday, 24 Oct 2026

In recent months, desperate Americans have travelled to China to obtain the Chinese-made cancer drug that was approved by the US Food and Drug Administration but remained unavailable in the country for more than a year, according to a cancer-treatment awareness advocate who made the journey while his mother was battling the disease.

“I’m very thankful to all the development that companies in China have done because it saved my mum’s life,” Max Doppelt, chief executive of Patient Data Vault, a consultancy that connects cancer patients to clinical trials, told the South China Morning Post.

He added that he knew of at least 30 other Americans who had made the same trip.

Developed by China’s Dizal Pharmaceutical, sunvozertinib is a targeted lung cancer drug designed to treat adults with an advanced form of the illness, offering another treatment option for patients.

Doppelt said he decided to travel to Shanghai to obtain the drug after his mother’s lung cancer spread to her brain in January 2025, when she had about 10 tumours.

At a lung cancer conference, a doctor told him that if his mother “happened to have lived in China, she could just get it”, as the country had approved the drug in 2023.

“I became pretty obsessed over it because my first reaction was, well, why don’t we go to China?”

China’s Dizal Pharmaceutical developed the lung cancer drug sunvozertinib, which received US regulatory approval in July 2025. 

He flew to China and returned home with 26 boxes of the China-made drug.

AstraZeneca said on Thursday that sunvozertinib would be commercially available in the United States under the brand name Zegfrovy, after securing worldwide rights to develop and sell the drug from China’s Dizal Pharmaceutical.

The deal included a US$600 million upfront payment to Dizal, with a further US$900 million potentially payable upon meeting specific regulatory clearances, as well as tiered royalties on global sales of Zegfrovy.

“By making Zegfrovy available in the US, we are bringing an oral, mutation-specific treatment option to a distinct patient population with substantial unmet need,” 

“The world has flipped. It’s remarkable how China has become a powerhouse in drug discovery and is now leading,” 

-- SOUTH CHINA MORNING POST

MY COMMENTS: Dizal Pharma the Chinese pharmaceutical company has been marketing this lung cancer drug - oral application - in China since 2023.

It means lung cancer patients in China have access to a cure for lung cancer. 

The Americans have been delaying selling this drug in the US and other markets. The US drug company AstraZeneca has bought a franchise to sell this cancer drug in the US under a new brand name Zegfrovy. They also claim they have global rights to the same brandname  Zegfrovy.

Hello Menteri Kesihatan - tanyalah Dizal Pharma in China kalau Malaysia boleh beli ubat lung cancer ini under the original Chinese brand name sunvozertinib ? Deal direct dengan China.  

If you do not know then ask the people who know.

Jangan pula kita tunggu 10 tahun pun ubat baru ini tak sampai ke Malaysia. They are already seling this new cancer cure in China, the US and I am sure in other countries too.

Jangan Jadi Empat Kali Bodoh. Ingat Tak Pak Arab Tipu Dr Mahathir Beratus Juta Ringgit Dulu (Duit Kita)?

Here is an old story. Kebodohan awal.

• Pak Arab inventor associated with gomen-backed research company 
• Ínvolved hundreds of millions of ringgit in gomen financing and allegations about the company's technology, management and use of funds. 
• Funding: Gomen committed loan of RM437m. 
• By early 2005, RM228 million had reportedly been disbursed.
• 2005: Allegations of approximately RM50m fraud, mismanagement.
• Authorities froze company's finances, and police investigated. 
• 2006: Gomen pursued recovery of RM242 million in outstanding debt.
• 2008: Federal Court rejected their application to appeal 
• Gomen proceeded with winding up company
• A former independent director later wrote that the company's claimed intellectual property raised serious technical questions and that the authorities ultimately failed to build a legal case against the inventor.

Here is a new story.

S-----nk and its founder and CEO, M-------i, have been associated with several major financial controversies, substantial investment losses, corporate-governance disputes and legal proceedings.

1. Major Controversies and Financial Setbacks

1.1 The W----k investment

S-----nk invested approximately US$16b (RM64 billion) in W----k over several years. Embroiled in controversy surrounding its governance, founder A--m N-----n's leadership and its unsuccessful attempt to go public in 2019.

W----k filed for bankruptcy in November 2023.

S-----nk also faced legal disputes after abandoning a proposed US$3 billion share purchase from W----k investors in 2020.

1.2 G-------l Capital

S-----nk's V---n Fund invested approximately US$1.5 billion in G-------l Capital, a supply-chain finance company.

G-------l also provided financing to businesses backed by S-----nk. These overlapping relationships raised questions about conflicts of interest, credit risks and the allocation of losses.

G-------l collapsed in 2021, prompting scrutiny of its financing arrangements and the exposure of associated investment funds.

1.3 V---n Fund investment losses

S-----nk established its V---n Fund to make large investments in technology companies and rapidly growing startups.

Some investments performed poorly or lost substantial value. In May 2020, S-----nk reported approximately US$18b (RM72B) in V----n Fund operating losses for the fiscal year, amid declining valuations and problems involving companies such as W----k.

The losses prompted questions about the company's investment valuations, concentration of risk, debt exposure, transparency and governance.

The episode demonstrated the financial consequences of an aggressive investment strategy.

1.4 Technology-stock trading controversy

In 2020, S-----nk made large investments in US technology stocks and derivatives through an investment operation associated with its No------r unit.

Media reports raised questions about the unit's relationship with M-------i's personal financial interests and whether adequate safeguards existed to manage potential conflicts of interest.

M-------i reportedly denied that the arrangements created a conflict and defended the compensation structure associated with his investment expertise.

These reports established controversy and scrutiny. 

2. Investigations and Regulatory Scrutiny

2.1 US Securities and Exchange Commission

In March 2021, the US Securities and Exchange Commission confirmed that an investigation involving S-----nk-related trading activities was active and ongoing.

The matter arose amid scrutiny of the company's technology-stock trading and its N-------r investment unit.

2.2 US Federal Trade Commission

In 2025, the US Federal Trade Commission undertook an in-depth review of S-----nk's proposed acquisition of A----- C-------g. 

The transaction attracted regulatory attention because of its implications for competition and the technology sector, particularly the growing importance of AI chips.

2.3 J-----se tax-reporting issue

In 2020, media reports said that J-----se tax authorities had identified approximately xy billion in under-reported income associated with S-----nk for the fiscal year ending March 2019.

The company reportedly attributed the issue to accounting-period errors, calculations and income reporting involving overseas affiliates.

3. Questions Concerning M-------i's Personal Financial Interests

3.1 Potential conflicts of interest

Media reporting has raised questions about M-------i's personal financial arrangements in connection with investment operations associated with S-----nk.

These reports have focused on whether his interests were adequately separated from those of the company and its shareholders.

3.2 Personal exposure to investment losses

In November 2022, Bloomberg reported that M-------i faced approximately US$4.7b (RM18.8b) in personal financial exposure under investment arrangements connected to his compensation.

Losses in the V----n Fund had reduced the value of interests associated with those arrangements.

The situation illustrated how the company's investment strategy could expose both the corporate group and its founder to substantial financial risks.

4. W----k Governance and Shareholder Disputes

S-----nk's relationship with W----k generated litigation concerning control of the company and the cancellation of a proposed share purchase.

W----k's co-founder and a special committee representing other investors challenged S---bank's decision to terminate the proposed transaction. S-----nk disputed the claims.

5. More Recent Financial Risks: Artificial Intelligence Investments

S-----nk has increasingly focused on artificial intelligence, including a substantial investment in O----I and spending on AI-related infrastructure.

In May 2026, Reuters reported that S-----nk had recorded a substantial annual profit, driven in large part by gains associated with its O----I investment.

5.1 Debt and financing pressure

A July 2026 Reuters report said S-----nk had reopened discussions about a US$10b  loan backed by its O----I stake while facing a March 2027 deadline to repay a US$40b (RM160b)  bridge loan used to finance its O----I investment.

These reported financing requirements raise questions about liquidity, borrowing costs and the concentration of financial exposure in a limited number of major investments.

5.2 Credit-market concerns

In October 2026, Bloomberg reported that the cost of insuring S-----nk's debt against default had risen to its highest level in nearly four years, amid concerns about AI spending, financing costs and potential acquisitions.

Such movements can indicate increased investor concern about credit risk. 

5.3 High-cost borrowing

An October 2026 report highlighted a reported US$11b (RM44b) high-yield bond offering by S-----nk and the pressure to generate returns from its AI investment strategy.

The central financial question is whether the company can generate sufficient returns to justify the scale and cost of its investments.

These risks are material, but the ultimate outcome remains uncertain.

6. Overall Assessment

Legal and regulatory exposure

S-----nk has faced genuine regulatory scrutiny and civil litigation. The SEC confirmed an active investigation involving S-----nk-related trading activities in 2021, although the final outcome is not established by the sources reviewed here.

Investment performance

The W----k collapse, G-------l-related losses and earlier V----n Fund setbacks demonstrate that S-----nk has made some exceptionally costly investment decisions.

OSTB: Dont say nobody warned you. This is free advise.

World According to Sam: Wan Saiful Porking Policy Proposal in Parliament"

 

RUSSIA HAS DEVELOPED US$500 (RM2,000) YOLKA DRONE HUNTER - RANGE 3 KM, CAMERA GUIDED

 

FRIDAY NOTES (23/10/26) FROM THE QURAN - SURELY THE UGLIEST VOICE IS THE VOICE OF THE DONKEY

Non Muslims can read this too. It will take less than a minute.

Surah Luqman 31:18  وَلَا تُصَعِّرْ خَدَّكَ لِلنَّاسِ وَلَا تَمْشِ فِي الْأَرْضِ مَرَحًا ۖ إِنَّ اللَّهَ لَا يُحِبُّ كُلَّ مُخْتَالٍ فَخُورٍ

“And do not turn your cheek in contempt toward people and do not walk through the earth boastfully. Indeed, Allah does not like everyone who is self-deluded, boastful.”

Surah Luqman 31:19   وَاقْصِدْ فِي مَشْيِكَ وَاغْضُضْ مِن صَوْتِكَ ۚ إِنَّ أَنكَرَ الْأَصْوَاتِ لَصَوْتُ الْحَمِيرِ
“And be moderate in your pace and lower your voice; indeed, the most disagreeable of sounds is the voice of donkeys.”